Welcome to Cardiology Today/Healio.com FDA Highlights in Cardiology. This collection of articles includes recent FDA news and announcements in the field of cardiology, with expert perspective and commentary on major decisions and the ways in which they will affect your clinical practice.


FDA advisory panel recommends approval for dapagliflozin

The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 10-4 in favor of the updated cardiovascular risk profile of the investigational sodium-glucose co-transporter 2 inhibitor, dapagliflozin. The committee also voted 13-1 in favor of the agent as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Miriam Vos, MD, MSPH

Miriam Vos

"Diabetes remains an epidemic with significant morbidity and mortality. Improvements in metabolic parameters as associated with improved outcomes. Numerous treatment options are available but each has its limitations; a need remains for new therapeutic options," Harold E. Bays, MD, FTOS, FACE, FNLA, medical director and president of the Louisville Metabolic and Atherosclerosis Research Center Inc., said during the meeting. More »


Featured News

  • FDA approvals
  • FDA approves next-generation EES

  • November 25, 2013
  • Boston Scientific has announced that its Promus Premier everolimus-eluting platinum chromium stent system has received FDA approval for the treatment of...More »